Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
The PROCLAIM Registry is a US-based, multicenter Registry designed to establish a high
quality observational database of real-world clinical data on HD IL-2 when used to treat
patients with mRCC, mM or other malignancies. The Registry will not, in any way, suggest
changes in the treatment or management of the patients enrolled in the Registry. Therefore,
physicians will continue to manage and treat patients according to standard of care and
their own judgment.
The PROCLAIM Registry will start with a retrospective pilot data collection from a
de-identified finite number of patient cases abstracted from their existing medical charts.
The features collected will be identical to those planned for the prospective registry. The
resulting database will be used to formulate hypotheses to be tested using the prospective
registry database. Patients utilized in the retrospective analysis will be excluded from the
prospective portion of the Registry.
In the prospective portion of the Registry, sites will enroll patients who are expected to
start a course of HD IL-2 therapy. Once enrolled, the patient must receive at least one dose
of HD IL-2 to remain in the Registry. Patients will be treated and followed according to the
site's standard of care. This Registry will in no way induce changes in the management of
individual patients. Clinical data features will be entered into an Electronic Data Capture
(EDC) system, and organized into a registry database.
The data contained in the registry database will be observational data. The PROCLAIM
Registry does not stipulate patient care, specific visits or interventions but merely
surveys standardized parameters regarding HD IL-2 and associated therapies as they are
applied by treatment centers. The collection of standard data over time permits the
evaluation of trends in patient survival and subsequent therapy exposure. The database will
be used to answer future queries formulated by researchers.
Observational
Time Perspective: Prospective
A source of observational data that can be used to report and query patient care patterns, clinical outcomes and trends from high dose IL-2 or Proleukin therapy in treating malignant melanoma, or renal cell carcinoma or other malignancies.
12 months
No
James Lowder, MD
Principal Investigator
Prometheus Laboratories
United States: Institutional Review Board
10PLK13
NCT01415167
August 2011
August 2016
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
University of Iowa Hospitals and Clinics | Iowa City, Iowa 52242 |
Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Loyola University Medical Center | Maywood, Illinois 60153 |
Moores UCSD Cancer Center | La Jolla, California 92093-0658 |
Saint Luke's-Roosevelt Hospital Center | New York, New York 10019 |
Duke University Medical Center | Durham, North Carolina 27710 |
Oncology Specialists, SC | Park Ridge, Illinois 60068 |
Providence Portland Medical Center | Portland, Oregon 97213-3635 |
Dartmouth Hitchcock Medical Center | Lebanon, New Hampshire 03756 |
Blumenthal Cancer Center | Charlotte, North Carolina 28203 |
USC Norris Cancer Center | Los Angeles, California 90033 |
Wake Forest University Baptist Medical Center | Winston-Salem, North Carolina 27157 |
Rush Pres St Lukes Medical Center | Chicago, Illinois 60612 |
Indiana University Melvin and Bren Simon Center | Indianapolis, Indiana 46202 |
Mount Sinai Medical Center Comprehensive Cancer Center | Miami Beach, Florida 33140 |
The Baton Rouge Clinic, AMC | Baton Rouge, Louisiana 70808 |
University of Minnesota Masonic Cancer Center | Minneapolis, Minnesota 55455 |
Midwest Cancer Center - Legacy | Omaha, Nebraska 68130 |
University Hospitals Siedman Cancer Center | Cleveland, Ohio 44106 |
Saint Luke's Hospital and Health Network | Bethlehem, Pennsylvania 18015 |
Hillman Cancer Research Pavilion, Div. of Medical Oncology | Pittsburgh, Pennsylvania 15232 |